We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Genentech, Tercica, Insmed Settle Patent Suit

Law360 (March 7, 2007, 12:00 AM EST) -- Biotechnology companies Genentech Inc. and Tercica Inc. settled their lawsuit against rival start-up Insmed Inc. on Wednesday, ending a three-year-long patent scrimmage over Iplex, a drug used to treat hormone deficiencies in children.

In December, a California jury awarded $7.5 million plus royalties to Genentech and Tercica, after a “clean sweep” verdict found that Insmed had infringed on their patents for Iplex.

After an 11-day trial and seven days of deliberations, the jury ordered defendant Insmed to pay the Silicon Valley partners 15% royalties on up...
To view the full article, register now.